Compare Ishares Msci Brazil ETF (EWZ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Merck & Co., Inc. — how do they compare? Ishares Msci Brazil ETF trades at $43.48 (market cap $11.30B), while Merck & Co., Inc. trades at $146.07 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 31.1× Ishares Msci Brazil ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Ishares Msci Brazil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Merck & Co., Inc. for 98 Days on average.
| EWZ | MRK | |
|---|---|---|
Market Cap | $11.30B | $351.28B |
Volume | 44,036,597 | 7,969,665 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $156.43 |
52-Week Low | $28.79 | $82.49 |
Typical Hold Time | 50 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, is trading at $43.465, up 2.58% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows strong institutional interest with unusual options activity and new positions from firms like Empowered Funds. Recent news highlights Brazil's upcoming election as a key market driver, with investors positioning for potential policy shifts under different candidates.
The outlook for EWZ hinges on Brazil's political landscape and commodity trends. Investment opportunities include geographic diversification and exposure to Brazilian stimulus policies, while risks involve election volatility and US-Brazil trade tensions. Wall Street shows cautious optimism with significant institutional accumulation despite competitive pressure from lower-fee alternatives like FLBR.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
